NO20060143L - Farmasoytisk preparat og fremgangsmate for a lindre bivirkninger av ostrogenerstatningsbehandling - Google Patents

Farmasoytisk preparat og fremgangsmate for a lindre bivirkninger av ostrogenerstatningsbehandling

Info

Publication number: NO20060143L
Authority: NO; Norway
Prior art keywords: alleviating; effects; pharmaceutical preparation; replacement therapy; estrogen replacement
Prior art date: 2003-06-11

Application number

NO20060143A

Other languages

English (en)

Norwegian (no)

Inventor

Vadim Ivanov

Aleksandra Niedzwiecki

Matthias Rath

Shrirang Netke

Original Assignee

Matthias Rath

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-11

Filing date

2006-01-10

Publication date

2006-03-07

2006-01-10 Application filed by Matthias Rath filed Critical Matthias Rath

2006-03-07 Publication of NO20060143L publication Critical patent/NO20060143L/no

Links

238000000034 method Methods 0.000 title abstract 2
238000009164 estrogen replacement therapy Methods 0.000 title 1
239000000825 pharmaceutical preparation Substances 0.000 title 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 4
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
239000004472 Lysine Substances 0.000 abstract 2
229960005070 ascorbic acid Drugs 0.000 abstract 2
235000010323 ascorbic acid Nutrition 0.000 abstract 2
239000011668 ascorbic acid Substances 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
239000004475 Arginine Substances 0.000 abstract 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 abstract 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 abstract 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 abstract 1
244000269722 Thea sinensis Species 0.000 abstract 1
229960004308 acetylcysteine Drugs 0.000 abstract 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
239000010949 copper Substances 0.000 abstract 1
229910052802 copper Inorganic materials 0.000 abstract 1
239000003085 diluting agent Substances 0.000 abstract 1
235000009569 green tea Nutrition 0.000 abstract 1
229940094952 green tea extract Drugs 0.000 abstract 1
235000020688 green tea extract Nutrition 0.000 abstract 1
229910052749 magnesium Inorganic materials 0.000 abstract 1
239000011777 magnesium Substances 0.000 abstract 1
239000011572 manganese Substances 0.000 abstract 1
229910052748 manganese Inorganic materials 0.000 abstract 1
230000001575 pathological effect Effects 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
239000011669 selenium Substances 0.000 abstract 1
229910052711 selenium Inorganic materials 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/32—Tin compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Natural Medicines & Medicinal Plants (AREA)
Inorganic Chemistry (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Microbiology (AREA)
Medical Informatics (AREA)
Mycology (AREA)
Botany (AREA)
Alternative & Traditional Medicine (AREA)
Biotechnology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20060143A 2003-06-11 2006-01-10 Farmasoytisk preparat og fremgangsmate for a lindre bivirkninger av ostrogenerstatningsbehandling NO20060143L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10/460,023 US20040253319A1 (en)	2003-06-11	2003-06-11	Pharmaceutical compositions and method for alleviating side-effects of estrogen replacement therapy
PCT/US2004/018627 WO2004110383A2 (fr)	2003-06-11	2004-06-11	Composition pharmaceutique et technique permettant d'attenuer les effets secondaires de therapie de remplacement d'oestrogenes

Publications (1)

Publication Number	Publication Date
NO20060143L true NO20060143L (no)	2006-03-07

Family

ID=33510922

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20060143A NO20060143L (no)	2003-06-11	2006-01-10	Farmasoytisk preparat og fremgangsmate for a lindre bivirkninger av ostrogenerstatningsbehandling

Country Status (13)

Country	Link
US (1)	US20040253319A1 (fr)
EP (1)	EP1638528A4 (fr)
JP (1)	JP2007500754A (fr)
KR (1)	KR20060063797A (fr)
CN (1)	CN1997353A (fr)
AU (1)	AU2004247145A1 (fr)
CA (1)	CA2529225A1 (fr)
NO (1)	NO20060143L (fr)
PL (1)	PL379515A1 (fr)
RU (1)	RU2006100031A (fr)
TR (1)	TR200600315T1 (fr)
WO (1)	WO2004110383A2 (fr)
ZA (1)	ZA200600038B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2004245017A1 (en) *	2003-05-30	2004-12-16	Matthias Rath	Nutritional composition and method of inhibiting smooth muscle cell contraction thereof
US20070265211A1 (en) *	2006-05-12	2007-11-15	Matthias Rath	Novel composition and method effective in inhibiting the atherogenic process
GB0624340D0 (en) *	2006-12-06	2007-01-17	Nature Therapeutics Ltd	Antimicrobial composition
US20080319051A1 (en) *	2007-06-22	2008-12-25	Bionovo, Inc.	Liquiritigenin and derivatives as selective estrogen receptor beta agonists
MX2012001729A (es)	2009-08-26	2012-06-13	Sanofi Sa	Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
WO2011157827A1 (fr)	2010-06-18	2011-12-22	Sanofi	Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8809325B2 (en)	2011-03-08	2014-08-19	Sanofi	Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
WO2012120058A1 (fr)	2011-03-08	2012-09-13	Sanofi	Dérivés d'oxathiazine substitués par des groupes benzyle ou hétérométhylène, leur procédé de production, leur utilisation comme médicament ainsi que produits pharmaceutiques les contenant et leur utilisation
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
ES2885523T3 (es)	2011-11-23	2021-12-14	Therapeuticsmd Inc	Formulaciones y terapias de reposición hormonal de combinación naturales
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
US20150196640A1 (en)	2012-06-18	2015-07-16	Therapeuticsmd, Inc.	Progesterone formulations having a desirable pk profile
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
JP2017516768A (ja)	2014-05-22	2017-06-22	セラピューティックスエムディーインコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ，Ｉｎｃ．	天然の併用ホルモン補充療法剤及び療法
AU2015296609A1 (en)	2014-07-29	2016-12-22	Therapeuticsmd, Inc.	Transdermal cream
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
WO2017173044A1 (fr)	2016-04-01	2017-10-05	Therapeuticsmd Inc.	Compositions d'hormones stéroïdes dans des huiles à chaîne moyenne
BR112018070199A2 (pt)	2016-04-01	2019-01-29	Therapeuticsmd Inc	composição farmacêutica de hormônio esteroide
JP2022506044A (ja)	2018-10-30	2022-01-17	ユニバーシティオブフロリダリサーチファウンデーション，インコーポレイティド	嚢胞性線維症を治療するためのアミノ酸組成物及び方法
US11633405B2 (en)	2020-02-07	2023-04-25	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical formulations
CN113244227B (zh) *	2020-02-12	2022-09-02	浙江医药股份有限公司新昌制药厂	一种17β-雌二醇与维生素C的分子复合物及其制备方法及应用
KR20210113716A (ko)	2020-03-09	2021-09-17	(주)아모레퍼시픽	성분 함량이 변화된 녹차 추출물을 포함하는 여성호르몬 조절 이상 질환 또는 증상의 예방, 완화, 개선 또는 치료용 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4554101A (en) *	1981-01-09	1985-11-19	New York Blood Center, Inc.	Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4980358A (en) *	1988-04-04	1990-12-25	George D. McAdory	Method employing gonadal hormones and dopamine agonist intended for combined use in the improvement of lymphocyte function
US5514382A (en) *	1994-10-17	1996-05-07	Sultenfuss; Sherry	Daily vitamin and mineral supplement for women
US5569459A (en) *	1995-02-15	1996-10-29	Bio-Virus Research Incorporated	Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders
US5998401A (en) *	1995-02-28	1999-12-07	Eli Lilly And Company	Naphthyl compounds, intermediates, compositions, and methods
US5654011A (en) *	1996-07-30	1997-08-05	Energetics, Inc.	Dietary supplements
EP1068868A3 (fr) *	1997-07-08	2001-01-31	Rath, Matthias, Dr. med.	Compositions synergiques comportant l'ascorbate et la lysine pour des états associés à la dégénération de la matrice extracellulaire
US6086915A (en) *	1998-04-01	2000-07-11	Bioresponse L.L.C.	Compositions and methods of adjusting steroid hormone metabolism through phytochemicals
WO2000007607A1 (fr) *	1998-08-04	2000-02-17	Kosbab, John, V.	Compositions nutritives et therapeutiques pour le traitement du cancer
ATE549939T1 (de) *	1999-02-24	2012-04-15	Iams Company	Diätzusammensetzungen und verfahren
US6914073B2 (en) *	1999-03-18	2005-07-05	Bristol Myers Squibb Company	Vitamin formulation for cardiovascular health
US6479545B1 (en) *	1999-09-30	2002-11-12	Drugtech Corporation	Formulation for menopausal women
KR100379323B1 (ko) *	2000-02-29	2003-04-08	삼아약품 주식회사	카테킨을 포함하는 관상동맥 재협착 예방 및 치료용 약학조성물
AU2002243643A1 (en) *	2001-01-25	2002-08-06	Yale University	Estradiol-16alpha-carboxylic acid esters as locally active estrogens
CN1555266A (zh) *	2001-03-16	2004-12-15		激素替代疗法
ES2272555T3 (es) *	2001-12-14	2007-05-01	Matthias Rath	Composicion de estrogeno y otras hormonas con ascorbato, lisina, prol ina y otras sustancias.
PL215159B1 (pl) *	2002-01-11	2013-10-31	Matthias Rath	Odzywcza kompozycja farmaceutyczna uzyteczna w leczeniu raka oraz jej zastosowanie
US7101576B2 (en) *	2002-04-12	2006-09-05	Elan Pharma International Limited	Nanoparticulate megestrol formulations
US7445807B2 (en) *	2002-10-15	2008-11-04	Western Holdings, Llc	Agglomerated granular protein-rich nutritional supplement

2003
- 2003-06-11 US US10/460,023 patent/US20040253319A1/en not_active Abandoned
2004
- 2004-06-11 EP EP04755028A patent/EP1638528A4/fr not_active Withdrawn
- 2004-06-11 AU AU2004247145A patent/AU2004247145A1/en not_active Abandoned
- 2004-06-11 KR KR1020057023926A patent/KR20060063797A/ko not_active Ceased
- 2004-06-11 CA CA002529225A patent/CA2529225A1/fr not_active Abandoned
- 2004-06-11 RU RU2006100031/15A patent/RU2006100031A/ru unknown
- 2004-06-11 PL PL379515A patent/PL379515A1/pl unknown
- 2004-06-11 TR TR2006/00315T patent/TR200600315T1/xx unknown
- 2004-06-11 ZA ZA200600038A patent/ZA200600038B/en unknown
- 2004-06-11 CN CNA200480022589XA patent/CN1997353A/zh active Pending
- 2004-06-11 JP JP2006533732A patent/JP2007500754A/ja active Pending
- 2004-06-11 WO PCT/US2004/018627 patent/WO2004110383A2/fr active Application Filing
2006
- 2006-01-10 NO NO20060143A patent/NO20060143L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
KR20060063797A (ko)	2006-06-12
WO2004110383A3 (fr)	2005-04-07
CN1997353A (zh)	2007-07-11
US20040253319A1 (en)	2004-12-16
AU2004247145A1 (en)	2004-12-23
TR200600315T1 (tr)	2006-08-21
RU2006100031A (ru)	2007-07-20
WO2004110383A2 (fr)	2004-12-23
EP1638528A4 (fr)	2007-03-07
ZA200600038B (en)	2007-03-28
CA2529225A1 (fr)	2004-12-23
JP2007500754A (ja)	2007-01-18
EP1638528A2 (fr)	2006-03-29
PL379515A1 (pl)	2006-10-02

Legal Events

Date	Code	Title	Description
2009-02-02	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20060143L (no)	2006-03-07	Farmasoytisk preparat og fremgangsmate for a lindre bivirkninger av ostrogenerstatningsbehandling
IL173257A0 (en)	2006-06-11	Composition and method for facilitating bone healing
WO2004032827A3 (fr)	2004-10-14	Inhibiteurs du virus de l'hepatite c
WO2002060926A3 (fr)	2003-03-13	Inhibiteurs du virus de l'hepatite c
WO2001064639A3 (fr)	2002-02-28	Amides inhibant la pde iv, compositions et procedes de traitement
WO2004043339A3 (fr)	2004-07-22	Inhibiteurs du virus de l'hepatite c a base de cycloalkyle p1' substitue
WO2002008244A3 (fr)	2003-06-19	Nouveau peptide sous forme d'inhibiteurs de protease a serine ns3 d'hepatite virale c
WO2002018369A8 (fr)	2003-11-06	Inhibiteurs peptidomimetiques de protease
WO2002008256A3 (fr)	2002-08-29	Nouveaux peptides utilises comme inhibiteurs de serine ns3 protease du virus de l'hepatite c
WO2002008251A3 (fr)	2003-01-09	Nouveaux peptides utilises comme inhibiteurs de ns3-serine protease du virus de l'hepatite c
CA2473070A1 (fr)	2003-07-31	Composes de proline utilises en tant qu'inhibiteurs de la serine protease ns3 dans le traitement d'une infection par le virus de l'hepatite c
WO2002048157A3 (fr)	2003-03-27	Imidazolidinones et leurs derives associes, utiles en tant qu'inhibiteurs des proteases ns3 du virus de l'hepatite c
WO2001081325A3 (fr)	2002-08-01	Inhibiteurs macrocycliques de la protease ns3-serine du virus de l'hepatite c comprenant des fractions p2 alkyle et aryle alanine
AU2002360592A1 (en)	2003-07-09	Inhibitors of hepatitis c virus
EP1506000A4 (fr)	2005-06-15	Sulfamides heterocycliques en tant qu'inhibiteurs du virus de l'hepatite c
EP0981352B8 (fr)	2009-06-17	Utilisation d' aplidine pour le traitement des maladies cardio-vasculaires
CN105968101B (zh)	2019-03-01	作为丙型肝炎抑制剂的化合物及其在药物中的应用
AU2001286003A1 (en)	2002-03-04	Aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same
BRPI0414072A (pt)	2006-10-24	composição farmacêutica e seus usos para o retardo de doenças cardiovasculares
WO2006019685A3 (fr)	2006-06-15	Composes et leur preparation pour le traitement de la maladie d'alzheimer par inhibition de la production de peptides beta-amyloides
WO2001095785A3 (fr)	2003-09-12	Modulation de la reponse immunitaire et methodes basees sur ladite modulation
AU2001284154A1 (en)	2002-03-04	Aminoalkenylbenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same
Hartati et al.	2018	Antiviral effect of Archidendron pauciflorum leaves extract to hepatitis C virus: An in vitro study in JFH-1 strain
JP2001178368A (ja)	2001-07-03	高品質インスタントティーの製造方法
MY141756A (en)	2010-06-30	Use of phenoxyacetic acid derivatives for treating hyperactive bladder